What is the 13F Pro Quality Score for TARA?

13F Pro ranks Protara Therapeutics, Inc. (TARA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TARA's current score at https://13fpro.ai/research/TARA (free sign-up required for the full ranking).

Where does 13F Pro source TARA data?

All Protara Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Protara Therapeutics, Inc. files with the SEC under CIK 1359931. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TARA in?

Protara Therapeutics, Inc. (TARA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TARA research updated on 13F Pro?

TARA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Protara Therapeutics, Inc.(TARA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1359931 TARA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $2.9M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

TARA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Protara Therapeutics, Inc. (TARA), a Healthcare sector company. TARA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $2.9m in revenue. Based on the latest XBRL financial filings (Q1 2026), Protara Therapeutics, Inc. reports net income of $-17.8M, free cash flow of $-21.3M. Top institutional holders of TARA by reported 13-F value include JANUS HENDERSON GROUP PLC, BlackRock,, Velan Capital Investment Management, based on the most recent SEC filings. TARA trades on the Nasdaq exchange and files with the SEC under CIK 1359931. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TARA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Protara Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-17.8M

Free Cash Flow

Q1 2026

$-21.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-28.7% YoY

$-57.4MFY 2025

FY22 $-66.0MFY23 $-40.4MFY24 $-44.6MFY25 $-57.4M

Operating Income

-31.3% YoY

$-64.5MFY 2025

FY22 $-67.1MFY23 $-43.6MFY24 $-49.2MFY25 $-64.5M

EPS (Diluted)

+38.2% YoY

$-1.34FY 2025

FY22 $-5.86FY23 $-3.57FY24 $-2.17FY25 $-1.34

Total Assets

+15.4% YoY

$209.5MFY 2025

FY22 $113.3MFY23 $79.0MFY24 $181.5MFY25 $209.5M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

-57.4% YoY

$-56.4MFY 2025

FY22 $-26.5MFY23 $-37.6MFY24 $-35.8MFY25 $-56.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-57.4M -28.7%	$-44.6M -10.4%	$-40.4M +38.7%	$-66.0M -39.6%	$-47.3M -39.1%	$-34.0M
Operating Income	$-64.5M -31.3%	$-49.2M -12.7%	$-43.6M +35.0%	$-67.1M -41.2%	$-47.5M -37.9%	$-34.4M
EPS (Diluted)	$-1.34 +38.2%	$-2.17 +39.2%	$-3.57 +39.1%	$-5.86 -39.2%	$-4.21	—
Total Assets	$209.5M +15.4%	$181.5M +129.8%	$79.0M -30.3%	$113.3M -34.4%	$172.6M -15.0%	$203.2M
Total Debt	—	—	—	—	$0.00	$0.00
Operating Cash Flow	$-56.4M -57.4%	$-35.8M +4.7%	$-37.6M -42.0%	$-26.5M +23.3%	$-34.5M -47.4%	$-23.4M

AI Insight: TARA Financial Trends

Protara is burning cash faster with no revenue generation, equity declining from $196M peak despite recent capital raise.

• Operating cash burn accelerated to $21M in Q1 2026, worst quarter on record, up from $17M in Q4 2025.

• Net losses widened to $18M in Q1 2026 from $13M in Q3 2025; six consecutive quarters of worsening performance.

• Equity eroded to $181M in Q1 2026 from peak of $196M in Q4 2025 despite no revenue offsetting losses.

⚠ Operating cash outflows now exceed $20M/quarter; runway exhaustion imminent without capital raise or strategic pivot.

⚠ No revenue reported across entire 9-quarter period; clinical-stage biotech remains pre-commercial with no inflection signals.

AI Insight: TARA Ratio Trends

Protara remains deeply unprofitable with ROIC deteriorating to -43.3% in Q1 2026, showing no path to profitability over the past two years.

• ROIC worsened from -35.6% in Q1 2025 to -43.3% in Q1 2026, a 7.7pp decline over four quarters.

• ROE deteriorated from -30.1% in Q1 2025 to -39.2% in Q1 2026, reflecting sustained operational losses.

• All profitability and return metrics remain negative across entire trailing period; no recovery evident.

⚠ Q1 2026 marks worst ROIC (-43.3%) and second-worst ROE (-39.2%) in dataset—acceleration of value destruction.

⚠ Persistent negative returns suggest cash burn and equity dilution; monitor cash runway and clinical milestones.

Get alerted when TARA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Protara Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TARA

JANUS HENDERSON GROUP PLC
$27.2M5,207,011 sh
BlackRock, Inc.
$17.7M3,394,968 sh
Velan Capital Investment Management LP
$14.8M2,834,652 sh
MILLENNIUM MANAGEMENT LLC
$14.8M2,831,208 sh
Blackstone Inc.
$11.8M2,265,514 sh
VANGUARD CAPITAL MANAGEMENT LLC
$11.0M2,119,018 sh
Sio Capital Management, LLC
$10.3M1,969,839 sh
ACORN CAPITAL ADVISORS, LLC
$9.1M1,752,115 sh
Integral Health Asset Management, LLC
$9.1M1,750,000 sh
AIGH Capital Management LLC
$8.5M1,622,733 sh

Fund	Value	Shares
JANUS HENDERSON GROUP PLC	$27.2M	5,207,011
BlackRock, Inc.	$17.7M	3,394,968
Velan Capital Investment Management LP	$14.8M	2,834,652
MILLENNIUM MANAGEMENT LLC	$14.8M	2,831,208
Blackstone Inc.	$11.8M	2,265,514
VANGUARD CAPITAL MANAGEMENT LLC	$11.0M	2,119,018
Sio Capital Management, LLC	$10.3M	1,969,839
ACORN CAPITAL ADVISORS, LLC	$9.1M	1,752,115
Integral Health Asset Management, LLC	$9.1M	1,750,000
AIGH Capital Management LLC	$8.5M	1,622,733

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TARA on your watchlist

Track score changes the day Protara Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TARA a good stock to buy?

13F Pro's AI-powered analysis of Protara Therapeutics, Inc. (TARA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TARA are available on the TARA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TARA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TARA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Protara Therapeutics, Inc.'s investment landscape.